Page 2 - Ipca Labs

Stocks to Watch: IndusInd Bank, Ipca Lab, Infosys, ICICI Securities, RVNL

Stocks to Watch on June 26, 2023: The Hinduja Group is in talks to invest Rs 10,000 crore to hike its stake in IndusInd Bank, as per media reports

Ipca shares drop nearly 3% after USFDA's 11 observations about MP facility

Company says it takes quality and compliance issues with 'utmost importance'

Stocks to Watch on Monday, June 5: SBI Life, Hero Moto, Bajaj Finserv, NTPC

Stocks to Watch today, June 5, 2023: Brent crude related stocks could see considerable action today as oil prices jumped over 2 per cent overnight, and another 2 per cent Monday morning

Ipca Labs plunges 16% in two days; hits 3-year low on Unichem stake buy

The acquisition will allow Ipca to re-enter US formulation generic market, however at 2.3x sales, as acquisition cost is expensive, given challenges and uncertainty associated with US market.

IPCA Labs stock hits valuation hurdle on Unichem stake acquisition

Unichem's facilities are compliant with US regulations, but it posted losses for nine months of FY23

Ipca Labs dips 9%, hits 52-wk low on plan to buy 33.4% stake in Unichem Lab

Brokerages believe the acquisition is expensive, given increased competition in the US generics oral solids space, rising regulatory risks and strong efforts needed to turnaround Unichem Labs

Ipca Laboratories to acquire 33% stake in Unichem for 1,034 crore

The acquisition is subject to the fulfilment of terms and conditions as per the share purchase agreement, and statutory approvals from the Competition Commission of India, the company added

Ipca Labs slips 5%, hits 52-week low on weak December quarter results

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Sensex zooms 651 pts; Nifty above 18,000; all sectors end in the green

In the broader markets, the BSE MidCap index added 0.7 per cent while the BSE SmallCap index gained 1.2 per cent.

Ipca Labs down 6% as stock turns ex-date for 1:1 split

The pharmaceutical company has fixed Tuesday, January 11, 2022, as the 'record date' for the members entitlement of sub-divided shares.

Buy these stocks for a 10% upside on MSCI's new foreign ownership norms

Ipca Labs has tripled in the last one year from the lows of Rs 817 and continues to hold the same strength and momentum. Charts indicate more headroom from the current levels

Ipca Labs rallies 9%, hits all-time high on hopes of healthy Q2 results

In Q2FY21, the company's Ebitda margins are likely to improve 740 basis points YoY to 28 per cent

Five mid-cap stars which refused to buckle during the coronavirus crisis

With markets recovering, midcaps have also rebounded and in fact, have outperformed benchmark indices by a good margin in the last two months

Nifty has strong resistance between 11,300 and 11,400: HDFC Securities

There is a lot of uncertainty and clear trend is not visible on the charts

Market Ahead, June 16: All you need to know before the opening bell

The SGX Nifty is up around 170 points from yesterday's close and is indicating an open at around 9,980 levels for the Nifty today

Market Ahead, June. 1: Top factors that could guide markets this week

SGX Nifty, which is up 130 points, is indicating a stronger opening for the Indian indices today

Price drives Indian pharmaceutical market growth to five-year high in FY20

Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out

Nifty to face stiff resistance at 9,500 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor